Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Migraines More Likely to Occur Around Menstruation, Medication May Prevent More than Half

28.07.2004


Approximately half of all women who seek clinical treatment for migraines have reported an association between migraine and menstruation, and a recent study confirms their experience. In another, unrelated study researchers have identified a drug therapy that is effective in reducing the occurrence or the severity and duration of menstrually associated migraines. Details and outcomes of both studies, and a related editorial, are published in the July 27 issue of Neurology.

Nearly one in five adult women experience migraine headaches, compared with one in twenty adult men. Menstrual migraine is defined as headache that occurs regularly in close relationship to the onset of menstruation (between two days prior to and during the first three days of bleeding). Until recently, studies documenting migraine and menstruation have included small numbers of women over few cycles, often combining data from women using hormonal treatments with those who were not. Also, data has not been collected regarding the difference between menstrual versus non-menstrual migraine attacks within the same woman, rather than comparing attacks within a total population.

Researchers from the City of London Migraine Clinic analyzed diary data from 155 women patients. All of the women tracked at least two cycles, with nearly half of the patients keeping diary cards over the course of four or more menstrual cycles.



Diary card analysis showed that in the five days preceding menstruation, women were 25 percent more likely to have migraine; migraine was 71 percent more likely to occur during the two days before menstruation. The chance of migraine was more than twofold on the first day of menstruation and within five days afterward.

Severe attacks were more likely to occur during the pre-menstruation and post-menstruation intervals compared to all other times of a woman’s cycle. Women were almost five times more likely to have a migraine associated with vomiting on or during days one to three of menstruation.

“Our study supports new International Headache Society diagnostic criteria regarding pure menstrual migraine and menstrually related migraine,” concluded study author Anne MacGregor, MFFP, of the City of London Migraine Clinic and St. Bartholomew’s Hospital, London.

Meanwhile, researchers led by Stephen D. Silberstein, MD, FACP, of Thomas Jefferson University in Philadelphia, studied the use of frovatriptan in the prevention of menstrually associated migraines.

“Women have long reported menstrually related migraines as prolonged and difficult to manage with conventional therapies,” said Silberstein. Frovatriptan, indicated for acute treatment of migraine, has a long therapeutic life and is generally well tolerated, making it a natural agent to study as a preventive therapy.

This double-blind, placebo-controlled, three-way crossover study involved 443 patients from 36 U.S. centers. Patients were randomly assigned to placebo, 2.5 mg frovatriptan once daily and 2.5 mg frovatriptan twice daily for each of three menstrual cycles. The six-day treatment started two days before the anticipated start of menstrually associated migraine (previously determined by each participant).

Use of frovatriptan reduced the occurrence of migraine, with the incidence of migraine using placebo at 67 percent, with once-daily frovatriptan at 52 percent, and twice-daily frovatriptan at 41 percent. Both frovatriptan regimens also reduced migraine severity, duration and the use of additional migraine medication.

“More than half of patients who used frovatriptan 2.5 mg twice daily had no menstruation-associated migraine,” noted Silberstein. Study findings are consistent with the long duration of action of frovatriptan that has been observed in studies of acute treatment of migraine. He concluded, “The size of our study and the level of statistical significance obtained make our results very robust.”

The study by MacGregor et al was supported by grants from the Migraine Action Association and the Golden Charitable Trust. The study by Silberstein et al received support from Vernalis, Ltd., a producer of frovatriptan.

| newswise
Further information:
http://www.aan.com

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Plant escape from waterlogging

17.10.2017 | Life Sciences

Study suggests oysters offer hot spot for reducing nutrient pollution

17.10.2017 | Life Sciences

Breaking: the first light from two neutron stars merging

17.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>